Registry of Lobbyists

Registration - In-house Corporation

Pfizer Canada ULC / Najah Sampson, President

Registration Information

In-house Corporation name: Pfizer Canada ULC
Responsible Officer Name: Najah Sampson, President 
Responsible Officer Change History
Initial registration start date: 2007-04-27
Registration status: Active
Registration Number: 951977-15283

Associated Communications

Total Number of Communication Reports: 284

Monthly communication reports in the last 6 months: 4

Version 3 of 34 (2008-06-06 to 2009-05-13)

Version 3 of 34 (2008-06-06 to 2009-05-13) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Pfizer Canada ULC
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC  H9J 2M5
Canada
Telephone number: 514-426-7417
Fax number: 514-426-6835  
Responsible officer name and position during the period of this registration: Paul Lévesque, Président et chef de la direction  
Description of activities: Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals.
 
The client is a subsidiary of the following parent companies: PFIZER INC
235 EAST 42ND STREET
NEW YORK, NY
United States of America 10017-5755

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Toni Bothwell
Position title: Site Leader PGM Orangeville PAH
Public offices held: No
 
Name: David Fortier
Position title: Director, Strategy & Health Policy
Public offices held: No
 
Name: Nicolas Gagnon
Position title: Manager, Pricing
Public offices held: Yes
 
Name: John Helou
Position title: Vice President, Public Affairs & Stakeholder Relations
Public offices held: No
 
Name: Steven Hogue
Position title: Manager, Federal Relations
Public offices held: Yes
 
Name: Paul Lévesque
Position title: President & CEO
Public offices held: No
 
Name: Darren Noseworthy
Position title: Vice President & General Counsel
Public offices held: No
 
Name: Bernard Prigent
Position title: Vice President and Medical Director
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Agriculture and Agri-Food Canada (AAFC), Canadian Agency for Drugs and Technologies in Health (CADTH), Canadian Expert Drug Advisory Committee (CEDAC), Canadian Heritage (PCH), Canadian Institute for Health Research, Canadian International Development Agency (CIDA), Competition Tribunal (CT), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Justice Canada (JC), Members of the House of Commons, National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Works and Government Services Canada, Revenue Canada (RC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Other types: As part of Industry Associations and Delegations eg. Rx&D, BIOTECanada, Chamber of Commerce, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Health, Access to Information, Competition Policies and Regulations, Cross-border Trade, Federally-funded Health Benefits Program, Fiscal Policies and Regulations, Health, Health Research Policies, Regulations and Ethnics, Industry, Intellectual Property, Inter-governmental Affairs, International Trade, Pharmaceutical Policies and Regulations, Regional Development, Science and Technology
 
Subject Matter: Retrospective: Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants.
Subject Matter: Prospective: Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants.
 

Details Regarding the Identified Subject Matter

Categories Description
Regulation Access to Information Act & Regulations
Legislative Proposal, Regulation C-51 (An Act to Amend to Food and Drugs Act) Regulations
Policy or Program Canadian Institute of Health Researchers (CIHR) and other Research Oriented Spending Programs
Policy or Program Canadian Strategy for Cancer Control
Grant, Contribution or Other Financial Benefit CIHR Grants
Regulation Clinical Trials Regulations (Division 5)
Policy or Program Common Drug Review Policies
Policy or Program, Legislative Proposal Competition Act Amendments, Competition Bureau Studies
Policy or Program Cross Border Trade
Regulation Data Protection/Patented Medicines Notice of Compliance Regulations [PM(NOC) Regulations]
Legislative Proposal Drug Product Review & Approval System
Regulation Drug Product Review & Approval System / Regulations (filing formats of drug submissions, i.e. electronic Common Technical Document (eCTD) providing review tools currently not listed in the regulations)
Policy or Program Federal Provincial Pharmaceutical Initiatives
Policy or Program Federal Tobacco Control Strategies
Regulation Food & Drug Regulations (Good Manufacturing Practices & Establishment Licensing)
Regulation Food & Drugs Act (Drug Review & Approval regulations, Amendments to FDA, Data protection, Direct-to-Consumer Advertising Regs, New Substance Notification Regulations, Clinical Registry and Disclosure Regulation)
Legislative Proposal Food and Drugs Act (Cross Border Trade [CBT], Drug Export Restrictions)
Policy or Program Generic Pricing Policies
Policy or Program Health Canada Pharmaceutical Policies and Guidelines
Policy or Program Health Canada Probationary / Progressive Licensing Framework
Policy or Program Health Canada Site Inspections' program
Policy or Program Health Canada Subsequent Entry Biologics Policies
Grant, Contribution or Other Financial Benefit Health Partners International Canada (HPIC) - Tax Credit for Pharmaceutical Donations
Policy or Program Improving the efficiency of the drug review and approval process (Health Canada's Blue Print/Progressive Licensing Framework)
Policy or Program National Pharmaceutical Strategy
Policy or Program Non-Insured Health Benefits (NIHB)
Regulation Patent Act (Patented Medicines (Notice of Compliance)) Regulations - Amendments to prices review board
Regulation, Bill or Resolution Patented Medicine Prices Review Board (PMPRB) Regulations
Policy or Program Post-Marketing Surveillance Initiatives
Policy or Program Science and Technology Policy
Policy or Program Veterans Affairs Drug Benefits Plan
Policy or Program Veterinary Drug Distribution (VDD) post- NOC (Notice of compliance) Manufacturing changes guidelines
Legislative Proposal Veterinary Drug Distribution (VDDs) Document on Antimicrobial Categorization

Subject matters added through a communication report:
Consumer Issues 2009-01-07, 2009-01-07, 2009-01-22
Taxation and Finance 2009-01-22



Date Modified: